Transdermal Or Percutaneous Patents (Class 424/449)
  • Patent number: 10918686
    Abstract: Disclosed is an oleo gel composition including essential combination of synergistically acting phyto-active materials, non-psychotropic phytocannabinoids from the plant of Cannabis sativa: Cannabidiol, Cannabidiolic acid, Cannabivarin and Cannabigerol in combination with extract of Olive europaea Fruit Oil, Mentha arvensis leaf oil, and Silica colloidal anhydrous ensuring the delivery of cannabinoids to the deep tissues in order to reduce pain and inflammation of skeletal muscles and joints caused by trauma or/and induced by arthritis/osteoarthritis.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 16, 2021
    Assignee: UAB Satimed
    Inventor: Juozas Siurkus
  • Patent number: 10918607
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 16, 2021
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Patent number: 10912734
    Abstract: A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: February 9, 2021
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Sarabjit Singh
  • Patent number: 10898489
    Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: January 26, 2021
    Assignee: Strategic Science & Technologies, LLC
    Inventor: Eric T. Fossel
  • Patent number: 10898503
    Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
    Type: Grant
    Filed: January 1, 2016
    Date of Patent: January 26, 2021
    Inventor: Mark Quang Nguyen
  • Patent number: 10888532
    Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains at least one drug selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof and a silicone-based adhesive base, and a mass per unit area of the adhesive layer is 30 to 90 g/m2.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 12, 2021
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Naoko Fujita, Takito Shima, Kazuya Kominami, Naoyuki Uchida
  • Patent number: 10874338
    Abstract: Devices, systems, methods and kits for releasably mounting a medical device on the body or skin of a user are provided. Embodiments include a holder or mounting unit or structure that retains a medical device in a fixed position on a body part of a user or host, such as on the surface of the skin, and/or provides physical and/or electrical coupling to one or more additional components which may be operatively positioned above and/or below the surface of the skin.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: December 29, 2020
    Assignee: ABBOTT DIABETES CARE INC.
    Inventor: Gary Ashley Stafford
  • Patent number: 10864172
    Abstract: A transdermal patch is provided for use during oil delivery to a user's skin. The patch has a first foam member and a second foam member positioned adjacent the first foam member. An adhesive member is attached to the second foam member for securing the patch to a user's skin. A release liner covers and extends across the adhesive member. A gap can be formed between the first foam member and the second foam member and surrounds the first foam member. The first foam member has a thickness which is greater than a thickness of the second foam member.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: December 15, 2020
    Assignee: CHEMSULTANTS INTERNATIONAL INC.
    Inventors: Berryinne Decker, Keith Muny, Gary Avalon, Brian Buehner
  • Patent number: 10806914
    Abstract: Disclosed are composite microneedles arrays including microneedles and a film overlaying the microneedles. The film includes a plurality of nano-sized structures fabricated thereon. Devices may be utilized for interacting with a component of the dermal connective tissue. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Devices may be beneficially utilized for delivery of an agent to a cell or tissue. Devices may be utilized to directly or indirectly alter cell behavior through the interaction of a fabricated nanotopography with the plasma membrane of a cell and/or with an extracellular matrix component.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 20, 2020
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventor: Russell Frederick Ross
  • Patent number: 10799691
    Abstract: A needle assembly for transdermal administration including a substrate having a first surface and a second surface opposite to the first surface, and fine needles projecting perpendicularly from the first surface. The substrate has grooves on at least one of the first surface and the second surface, and the grooves are formed such that the substrate is deformable following a surface shape of a skin to allow axes of the fine needles to extend in a direction normal to the surface of the skin.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: October 13, 2020
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventors: Daizo Uemura, Kazuhiko Shiomitsu
  • Patent number: 10786487
    Abstract: This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 29, 2020
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Mark D. Soll, Joseph K. Rosentel, Jr., James Pate, Natalya Shub, Monica Tejwani-Motwani, Carol Belansky
  • Patent number: 10786574
    Abstract: The present disclosure is directed to transdermal and moisturizing compositions.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 29, 2020
    Inventor: Steven Hoffman
  • Patent number: 10772871
    Abstract: Aspects of the invention include transdermal delivery devices for delivering dexmedetomine to a subject, where the transdermal delivery devices include a single layer matrix dexmedetomine composition. Transdermal delivery devices according to certain embodiments include dexmedetomidine and a pressure sensitive adhesive provided as a single layer formulation. Also provide are methods of using the subject transdermal delivery devices to deliver dexmedetomidine to a subject, as well as kits containing the transdermal delivery devices.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: September 15, 2020
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
  • Patent number: 10765749
    Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: September 8, 2020
    Assignees: ITOCHU CHEMICAL FRONTIER Corporation, OISHI KOSEIDO CO., LTD.
    Inventors: Tatsuya Mori, Naoyuki Saida
  • Patent number: 10758528
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: September 1, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 10758619
    Abstract: Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: September 1, 2020
    Assignees: THE OHIO STATE UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Susan R. Mallery, Peter E. Larsen, Gary D. Stoner, Steven P. Schwendeman, Kashappa-Goud Desai
  • Patent number: 10751265
    Abstract: A multilayer beauty care product or method is provided. The beauty care product has a water soluble film zone that includes a water soluble film forming polymer and a cosmetic composition with an effective amount of a skin active agent. The product also has a barrier patch having a backing layer and a pressure sensitive adhesive zone. The adhesive zone and the water soluble film zone are continuous, discontinuous, or a combination thereof. The product exhibits a dynamic modulus.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: August 25, 2020
    Assignee: The Procter & Gamble
    Inventors: Emily Charlotte Boswell, Jack Alan Hunter, Michael Joseph Roddy, Elizabeth Anne Wilder
  • Patent number: 10717904
    Abstract: An adhesive preparation containing bisoprolol includes a backing and a pressure-sensitive adhesive layer formed on one side of the backing. The pressure-sensitive adhesive layer contains a polymer prepared through copolymerization of monomer components including a hydroxyl group-containing monomer and an alkyl (meth)acrylate monomer (component (A)), a polymer prepared through copolymerization of monomer components including a methyl methacrylate monomer and a butyl methacrylate monomer (component (B)), and bisoprolol (component (C)).
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 21, 2020
    Assignee: TOA EIYO LTD.
    Inventors: Eriko Abe, Yu Tachikawa, Satoshi Ameyama, Naoko Urushihara, Jun Ishikura, Tetsuya Nakamura, Akira Yokouchi, Yoshitaka Inoue, Kazuhiro Aoyagi, Tomoya Tanaka, Naohiro Nishida, Kunihiro Minami
  • Patent number: 10716925
    Abstract: Disclosed is a micro-needle including a tip formed using medicine that penetrates into the skin and melts therein; and at least one guide groove each in a stepped shape inward from the outer surface of the tip, and provided to the tip. The micro-needle configured as above may be used to administer a fixed quantity of medicine within a relatively short period of time. Also, since a guide space stepped based on the tip is provided to a base that supports the tip, a large amount of medicine may easily penetrate into the skin.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: July 21, 2020
    Assignee: QuadMedicine
    Inventor: Sun Young Baek
  • Patent number: 10702469
    Abstract: A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, counter irritant, additional penetration enhancer and anti-oxidants and a process for preparing the same.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: July 7, 2020
    Assignee: TROIKAA PHARMACEUTICALS LTD.
    Inventor: Ketan R. Patel
  • Patent number: 10688159
    Abstract: A treatment for pruritus is described that is based upon amylase. The amylases (?-, ?-, ?-amylase) are noted for the cleavage of the ?-glycosidic bonds of polysaccharides, yielding lower molecular weight carbohydrate/sugar fragments. It has now been found that ?-amylase is effective in the reduction of pruritus (itching) of affected tissue.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: June 23, 2020
    Assignee: ROCHAL INDUSTRIES, LLC
    Inventors: Joseph Charles Salamone, Ann Beal Salamone, Kelly Xiaoyu Chen Leung, Katelyn Elizabeth Reilly
  • Patent number: 10675254
    Abstract: Iontophoretic devices for transdermal delivery of a sphingosine-1-phosphate receptor agonist active agent are provided. Also provided are methods of transdermally delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat immune system disorders such as multiple sclerosis. Packaged iontophoretic systems, kits including iontophoretic devices, and methods of making iontophoretic devices are also provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 9, 2020
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Adchara Pongpeerapat
  • Patent number: 10660863
    Abstract: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, said system being suitable for an application period of at least three days, comprising the layers arranged in the following order with respect to each other: a) a cover layer, b) an active substance layer comprising a polymer matrix containing the active substance, c) an adhesive layer comprising a contact adhesive, which consists of a mixture of one or more polyisobutylenes and one or more polybutenes, and d) a pull-off layer.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: May 26, 2020
    Assignee: Luye Pharma AG
    Inventors: Britta Langer, Björn Schurad, Heike Prinz
  • Patent number: 10660962
    Abstract: The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 26, 2020
    Assignee: CMPD Licensing, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge
  • Patent number: 10653700
    Abstract: The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: May 19, 2020
    Inventor: John Hsu
  • Patent number: 10632105
    Abstract: The invention relates to the selective targeting of specific ?2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the ?2c receptor subtype using an ?2c specific agonist or by blocking the ?2a receptor subtype using ?2a antagonists. A combination of an ?2c agonist and an ?2a antagonist is also provided for a synergistic effect. Alternatively, a large ?2 agonist can be used in combination with an ?2a antagonist to achieve specific stimulation of the ?2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 28, 2020
    Assignee: ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
    Inventors: Grégoire Courtine, Quentin Barraud, Pavel Musienko
  • Patent number: 10624862
    Abstract: The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: April 21, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Lutz Barnscheid, Sebastian Schwier, Anja Geißler
  • Patent number: 10624834
    Abstract: Disclosed is a composition that begins as a multi-phase structure including a plurality of immiscible liquids that, upon agitation, encapsulates and suspends one of the plurality of liquids (e.g., in spheres). In some embodiments, the composition includes a water phase and an anhydrous phase. The composition can include a thickener added to the water phase to allow the water molecules to encapsulate the anhydrous phase into spheres. The formed spheres are stable and can be configured to last for specific durations depending on modifications to the formula. In some embodiments, the spheres can release back into the multi-phase structure after a specific period of time. The formulations disclosed herein can act as a vehicle or a base formulation to which additional ingredients can be added. The disclosed formulation, in addition to enabling the intermixing of two immiscible liquids, can provide a number of additional benefits.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: April 21, 2020
    Assignee: Benchmark Cosmetic Laboratories, Inc.
    Inventors: Susan Goldsberry, Lyndon S. Garcines, Yen H. Ly
  • Patent number: 10603066
    Abstract: A minimally invasive skin treatment system includes a platform having a recessed area on its bottom and one or more injection ports orthogonal to its top, each injection port including a through-hole to the recessed area. The system includes an injection device including a needle slidably disposed in a selective port such that the needle passes into the recessed area and percutaneously through a dermis disposed within the recessed area. A nozzle is configured to discharge a fluid at a high pressure in a direction orthogonal to an axis of the needle and parallel to the top of the platform to cut create a plane of dissection within the subcutaneous tissue.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: March 31, 2020
    Assignee: ULTHERA, INC.
    Inventors: Sowmya Ballakur, Robert L. Clark, III, James E. Chomas, Ben F. Brian, III, David M. Clapper
  • Patent number: 10568905
    Abstract: A pharmaceutical composition useful for preventing and treating retinal neurodegeneration related diseases comprising chromium chloride and magnesium sulfate, thickening agent, penetration enhancer, and pharmaceutical acceptable carrier, diluent or excipient. Further disclosed is a method for treating and preventing retinal neurodegeneration related diseases utilizing the composition.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: February 25, 2020
    Assignee: Metabolic Therapy Inc.
    Inventor: Kenneth O. Russell
  • Patent number: 10568961
    Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: February 25, 2020
    Assignee: DENTSPLY SIRONA Inc.
    Inventors: Anil Kishen, Saji George
  • Patent number: 10557041
    Abstract: Anti-corrosion composition comprising at least a first polyisobutylene with a Staudinger index J0 ranging from about 15 cm3/g to about 98 cm3/g and an average relative molar mass MV ranging from about 32,000 g/mol to about 280,000 g/mol and at least a second polyisobutylene with a Staudinger index J0 ranging from about 105 cm3/g to about 238 cm3/g and an average relative molar mass MV ranging from about 350,000 g/mol to about 900,000 g/mol.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: February 11, 2020
    Assignee: DENSO-HOLDING GMBH & CO
    Inventors: Thomas Markus Kaiser, Oleg Gryshchuk
  • Patent number: 10548854
    Abstract: Transdermal patches and devices for delivery of therapeutic drug and/or cosmetic formulations through an intact or porated skin barrier are described. Active-infusion delivers controlled dosing over a period of time to provide long-term efficacy. Methods and devices for preparing active-infusion patches for controlled dose delivery by nonelectronic devices and methods of skin poration that is safe and painless are described.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: February 4, 2020
    Assignee: The Hong Kong University of Science and Technology
    Inventors: King Lun Yeung, Wai Kit Wong, Siu Ming Kwan, Li Yin Chau, Ho Yee Timothy Poon, Ming Hung Thomas Lee, Albert Hee Lum Chow
  • Patent number: 10553132
    Abstract: Provided are methods for creating a pressurized cadaver model used for surgical procedure training. In the method the internal jugular veins, common carotid arteries, brachial arteries, superficial femoral arteries and femoral veins thereof of a cadaver are exposed. One internal jugular vein is ligated and a drainage tube is disposed in the other internal jugular vein. An arterial catheter is inserted into one brachial artery and connected to a pressure transducer and an arterial cannula is placed in a carotid artery and connected to a fusion pump. Fluid is injected into the artery through the cannulated carotid artery. A representative example of the surgical procedure includes resuscitative endovascular balloon occlusion of the aorta.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: February 4, 2020
    Assignee: University of Maryland, Baltimore
    Inventors: Megan Brenner, Thomas Scalea
  • Patent number: 10543275
    Abstract: The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: January 28, 2020
    Assignee: MEDRX CO., LTD.
    Inventors: Hidetoshi Hamamoto, Katsuhiro Yamanaka, Takahiro Tanimoto
  • Patent number: 10525020
    Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: January 7, 2020
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Ute Geigenmuller, Doris Damian, Maciej Pacula, Mark A. DePristo
  • Patent number: 10508789
    Abstract: A hollow light guide luminaire where a light source conveys light through a light ingress surface of a nominally hollow light guide with a narrow portion and a wide portion. The light guide provides means of transporting light via total internal reflection within the light guide from the light source positioned at one of the narrow portion or the wide portion to the other of the wide portion or the narrow portion wherefrom light is emitted from the light guide into the environment surrounding the luminaire.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: December 17, 2019
    Assignee: LOOM INC.
    Inventor: Matthew Kennedy
  • Patent number: 10493254
    Abstract: Disclosed are a patch, system, and method for delivery of a permeant composition into a subject via at least one formed pathway through a biological membrane of the subject. The patch comprises a matrix, at least one hydrophilic permeant disposed within the matrix, wherein at least a portion of the permeant can dissolve in biological moisture received from the subject, and at least one permeability enhancer disposed within the matrix. Also disclosed are systems and methods for delivery of a permeant composition into a subject via at least one formed pathway through a skin layer of the subject.
    Type: Grant
    Filed: June 24, 2017
    Date of Patent: December 3, 2019
    Assignee: Nitto Denko Corporation
    Inventors: Frank Tagliaferri, Alan Smith, David Enscore, Gaurav Tolia, Mirek Baudys
  • Patent number: 10478455
    Abstract: Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: November 19, 2019
    Assignee: UCL BUSINESS LTD
    Inventors: Mervyn Singer, John Francis Martin, Alex Peter Dyson
  • Patent number: 10471131
    Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: November 12, 2019
    Assignee: Hybrid Medical, LLC
    Inventors: Jeff Twidwell, Joel Buckley, Harold Hoium
  • Patent number: 10463629
    Abstract: Embodiments of the invention provide patches for the transdermal delivery of iron-containing compositions to an individual suffering from an iron deficiency. Many embodiments provide an iontophoretic patch for the transdermal delivery of a therapeutically effective amount of iron. The patch comprises an electrode and a reservoir containing a composition comprising ionic iron for the delivery of the therapeutically effective amount of iron. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a therapeutically effective amount of iron to an individual suffering from one more forms of iron deficiency including iron deficiency anemia. Such methods can be used for treating and/or preventing the iron deficiency. The amount of delivered iron can be adjusted depending upon various treatment parameters such as patient weight and type and amount of iron deficiency.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: November 5, 2019
    Assignee: FE3 MEDICAL, INC.
    Inventor: Ronald J. Berenson
  • Patent number: 10463660
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 5, 2019
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 10449254
    Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: October 22, 2019
    Assignees: The Regents of the University of California, Triad National Security, LLC, Arizona Board of Regents c/o Northern Arizona University
    Inventors: Michael Zakrewsky, Samir Mitragotri, David T. Fox, Andrew Koppisch, Rico Del Sesto, Katherine Lovejoy
  • Patent number: 10449201
    Abstract: A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7-day continuous application.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: October 22, 2019
    Assignee: ALPHA TO OMEGA PHARMACEUTICAL CONSULTANTS, INC.
    Inventors: Fotios M. Plakogiannis, Donald McAfee, Nisarg Modi
  • Patent number: 10449173
    Abstract: The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: October 22, 2019
    Assignee: Allergan Sales, LLC
    Inventors: Scott Gochnour, Venkatesh Subramanyan, Michael W. Kimball
  • Patent number: 10449268
    Abstract: Dermal filler hydrogel compositions, methods of making them, and methods of using them to treat soft tissue conditions, such as wrinkles, are provided. The compositions contain a crosslinked hyaluronic acid-based polymer and one or more additional ingredients, and are stable to sterilization by heat and/or pressure treatment. The additional ingredients include vasoconstrictive agents, antioxidant agents, such as a ascorbic acid agents, and/or anesthetic agents.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 22, 2019
    Assignee: ALLERGAN INDUSTRIE, S.A.S.
    Inventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost, Sumit Paliwal, Dennis Van Epps
  • Patent number: 10441551
    Abstract: A patch comprises a backing and an adhesive layer laminated on at least one surface of the backing, in which the adhesive layer contains at least one selected from the group consisting of fentanyl and salts thereof, and contains an adhesive base material and an antioxidant having a sulfur atom in its molecule.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: October 15, 2019
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Atsushi Sonobe, Akio Takeuchi, Yasunori Takada
  • Patent number: 10426835
    Abstract: In a method of treating a patient having diffuse plaque and/or a plaque mass associated with Peyronie's disease in a penile region, a battery of tests is performed to quantify an initial state of parameters associated with Peyronie's disease in the patient. Low intensity shock wave therapy is applied to the plaque mass in the penile region, thereby softening the plaque mass and disrupting any calcification in the plaque mass. Carbon dioxide is injected into the plaque mass. The battery of tests is repeated to quantify a current state of parameters associated with Peyronie's disease in the patient and the current state is compared to the initial state. The aforementioned treatment steps are repeated until the current state differs from the initial state by at least a predetermined amount.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 1, 2019
    Assignee: BMR Medical LLC
    Inventors: Steven Morganstern, Carlos Becerra
  • Patent number: 10422765
    Abstract: Electrode systems are disclosed for measuring the concentration of an analyte under in vivo conditions, where the systems includes an electrode with immobilized enzyme molecules and an improved diffusion barrier that controls diffusion of the analyte from body fluid surrounding the electrode system to the enzyme molecules. Methods of making and using the system also are disclosed.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: September 24, 2019
    Assignee: ROCHE DIABETES CARE, INC.
    Inventors: Arnulf Staib, Marcel Thiele, Karl-Heinz Koelker, Ewald Rieger
  • Patent number: 10420921
    Abstract: The present invention provides, inter-alia, applicators comprising an array of microneedles for administration of a composition comprising a biocompatible ceramic material effective in augmentation of skin. In particular, the applicators and methods of the present invention are aimed at filling the undesired lines, wrinkles, depressed scars and folds of a subject's skin and restoring youthful fullness to the skin.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: September 24, 2019
    Inventor: Avraham Amir